KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.92), $0.04 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $7.17 million.

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.